Technology | 2020.09.24
Catalent Acquires New Biologics Facility to Create North American Clinical Manufacturing Center of Excellence
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it has acquired a new manufacturing facility in Bloomington, Indiana, to create a North American center of excellence for early-phase clinical biologics formulation development and drug product fill/finish services. The $14 million investment includes the acquisition, build-out, and qualification of the facility to begin supporting customer programs starting January 2021.
(PRWeb September 24, 2020)
Read the full story at https://www.prweb.com/releases/catalent_acquires_new_biologics_facility_to_create_north_american_clinical_manufacturing_center_of_excellence/prweb17421684.htm
For more information, please visit
https://www.prweb.com/releases/catalent_[...]f_excellence/prweb17421684.htm
